Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Cancer Therapies02:49

Cancer Therapies

9.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.7K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

7.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy and Tolerability of Zenocutuzumab in Advanced <i>NRG1</i> Fusion-Positive Cholangiocarcinoma: Results From the eNRGy Phase II Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Absence of co-occurrence between HER2 amplification and dMMR/MSI in a large multicentric colorectal cancer cohort.

Scientific reports·2026
Same author

WEE1 kinase inhibition to overcome acquired resistance to targeted therapies in colorectal cancer.

EMBO molecular medicine·2026
Same author

Mismatch Repair-Proficient Colorectal Cancer can evade Immune Surveillance Through an Intrinsic Suppressive Program.

Cancer discovery·2026
Same author

Locally advanced rectal cancer: what patients and practitioners should know about non-operative management.

EClinicalMedicine·2026
Same author

Degrees of H2AX phosphorylation correlate with unique features of the intratumoral immune microenvironment in colorectal carcinomas.

The oncologist·2026
Same journal

Circadian Homeostasis of Liver Metabolism Suppresses Hepatocarcinogenesis.

Cancer cell·2026
Same journal

Vascular RhoJ Is an Effective and Selective Target for Tumor Angiogenesis and Vascular Disruption.

Cancer cell·2026
Same journal

Intratumoral B cells under stress.

Cancer cell·2026
Same journal

Chronic stress unleashes an intratumor phage-fibroblast-B cell circuit to promote tumor growth.

Cancer cell·2026
Same journal

Molecular phenotypes and spatial archetypes: A new framework for cancer-associated fibroblasts.

Cancer cell·2026
Same journal

OpenIO: An open framework for AI-native immunotherapy.

Cancer cell·2026
See all related articles

Related Experiment Video

Updated: Dec 10, 2025

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

17.0K

Breaking Barriers in HER2+ Cancers.

Salvatore Siena1, Silvia Marsoni2, Andrea Sartore-Bianchi1

  • 1Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milano, Italy; Dipartimento di Oncologia ed Emato-Oncologia, Università degli Studi di Milano (La Statale), Milano, Italy.

Cancer Cell
|August 29, 2020
PubMed
Summary
This summary is machine-generated.

Trastuzumab deruxtecan significantly improves outcomes for patients with HER2-positive metastatic gastroesophageal cancer. This novel immunoconjugate offers new hope where other HER2-targeted therapies have shown limited benefit.

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.5K
Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
11:34

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on: December 5, 2017

12.9K

Related Experiment Videos

Last Updated: Dec 10, 2025

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

17.0K
Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.5K
Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
11:34

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on: December 5, 2017

12.9K

Area of Science:

  • Oncology
  • Medical Research
  • Pharmacology

Background:

  • Metastatic gastroesophageal carcinoma (GEA) with HER2-positive (HER2+) status has limited treatment options.
  • Trastuzumab is the only HER2-targeted therapy with demonstrated efficacy in HER2+ GEA.
  • There is a critical need for novel therapeutic strategies to improve patient survival and response rates.

Purpose of the Study:

  • To evaluate the efficacy and safety of the immunoconjugate trastuzumab deruxtecan in patients with HER2+ metastatic GEA.
  • To assess the impact of trastuzumab deruxtecan on response rates and overall survival.
  • To compare the benefits of trastuzumab deruxtecan against existing treatment paradigms.

Main Methods:

  • A clinical study involving patients diagnosed with HER2-positive metastatic gastroesophageal carcinoma.
  • Treatment administered included the immunoconjugate trastuzumab deruxtecan.
  • Key outcomes measured were objective response rate and overall survival.

Main Results:

  • Trastuzumab deruxtecan demonstrated unprecedented improvements in patient response.
  • Significant enhancements in overall survival were observed in the treatment group.
  • These findings represent a major advancement in the management of HER2+ GEA.

Conclusions:

  • Trastuzumab deruxtecan offers a highly effective treatment option for HER2-positive metastatic GEA.
  • The immunoconjugate provides substantial clinical benefit, surpassing previous HER2-targeted therapies.
  • This study highlights the potential of trastuzumab deruxtecan to change the standard of care for this patient population.